PharmaShots Weekly Snapshot (December 10 -15, 2018)

  1.  Novartis’
    Xolair (omalizumab) Receives EU’s Approval for Severe Allergic Asthma (SAA) and
    Chronic Spontaneous Urticaria (CSU)

    Published: 13 Dec, 2018 |
    Tags:
    Novartis, Xolair, (omalizumab), Receives, EU, Approval, Severe
    Allergic Asthma, (SAA), Chronic Spontaneous Urticaria (CSU)

    2.   Axovant
    Sciences Licenses Two Gene Therapy Programs from University of Massachusetts
    for Rare and Fatal Neurodegenerative Genetic Disorders

    Published: 13 Dec, 2018 |
    Tags:
    Axovant
    Sciences, Licenses, Two, Gene Therapy, Programs, University of Massachusetts,
    Rare, Fatal, Neurodegenerative Genetic Disorders

    3.   Vertex‘s
    Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic
    Fibrosis (CF) Aged 2 to 5 yrs.

    Published: 13 Dec, 2018 |
    Tags:
    Vertex, Orkambi, (lumacaftor/ivacaftor) ,Receives ,Health Canada,
    Approval, Cystic Fibrosis, (CF) ,Aged, 2yrs, 5 yrs, EMA, the US FDA

    4.   Eli
    Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for
    Systemic Lupus Erythematosus (SLE)

    Published:
    13 Dec, 2018 | Tags: Eli Lilly,
    Olumiant, (baricitinib), Receives, FDA, Fast Track Designation, Systemic Lupus
    Erythematosus, (SLE)

    5.   Lilly
    Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative
    Diseases

    Published:
    12 Dec, 2018 | Tags: Lilly,
    Collaborates, AC Immune, Develop, Candidates, Alzheimer Disease,
    Neurodegenerative Diseases

    6.   AstraZeneca
    and AVEO Oncology Enters into an Immuno-Oncology Clinical Collaboration     

    Published:
    12 Dec, 2018 | Tags: AstraZeneca,
    AVEO Oncology, Enters, Immuno-Oncology, Clinical Collaboration

    7.   Merck
    Collaborates with Instituto Butantan to Develop Vaccines for Dengue

    Published:
    11 Dec, 2018 | Tags: Merck, Collaborates,
    Instituto Butantan, Develop , Vaccines, Dengue Infection, TV003

    8.   Oxford
    BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for the Development
    of Five Bispecific Antibodies

    Published:
    11 Dec, 2018 | Tags: Oxford
    BioTherapeutics, Licenses, WuXi Biologics, WuXiBody Platform, Five Bispecific
    Antibodies

    9.   Circassia
    Plans to Exercise Option for the US Commercialization Rights for Tudorza
    (aclidinium) From AstraZeneca

    Published:
    11 Dec, 2018 | Tags: Circassia,
    Plans, Exercise, Option, the US, Commercialization, Rights, Tudorza,
    (aclidinium), AstraZeneca

    10. Astellas
    to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3
    Mutation, in the US

    Published:
    11 Dec, 2018 | Tags: Astellas,
    Launch, Xospata, (gilteritinib), R/R Acute Myeloid Leukemia, (AML), FLT3
    Mutation, the US

    11. Sandoz
    Receives FDA’s Clearance for reSET-O, a Medical Mobile App for Opioid Use
    Disorder (OUD)

    Published:
    10 Dec, 2018 | Tags: Sandoz,
    Receives, FDA, Clearance, reSET-O, Medical, Mobile App, Opioid Use Disorder
    (OUD)

    12. Shionogi
    Signs a Research Collaboration with UBE Industries for the Development of
    Anti-RS Virus Drug Candidates

    Published:
    10 Dec, 2018 | Tags: Shionogi,
    Signs, Research, Collaboration, UBE Industries, Development, Anti-RS Virus Drug
    Candidates

    13. Novartis
    Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA
    trials for (HR+/HER2-) Advanced Breast Cancer

    Published:
    8 Dec, 2018|Tags: Novartis,
    Reports, Results, Kisqali (ribociclib), Endocrine Therapy, P-III, MONALEESA
    trials, (HR+/HER2-), Advanced Breast Cancer

    14. Bristol-Myers
    (BMS) Collaborates with Vedanta Biosciences to Develop Combination Therapy for
    Advanced or Metastatic Cancers

    Published:
    10 Dec, 2018|Tags: Bristol-Myers
    (BMS), Collaborates, Vedanta Biosciences, Develop, Combination, Therapy,
    Advanced or Metastatic Cancers, Opdivo, (nivolumab), VE800

    15. AstraZeneca
    Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial
    for Advanced Head and Neck Cancer

    Published:
    10 Dec, 2018|Tags: AstraZeneca, Reports, Imfinzi,
    (durvalumab), tremelimumab, Results, P-III, EAGLE trial, Advanced Head and Neck
    Cancer

    16. Merck
    Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express
    Platform 

          Published: 10 Dec, 2018|Tags: Merck, Licenses,
    Cyclica, In-Silico, Artificial Intelligence (AI), Ligand Express Platform 

    17. Daiichi
    Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for
    HER2 Low Expressing Metastatic Breast Cancer

          Published:
    8 Dec, 2018|Tags:
    Daiichi, Reports, Results,
    [Fam-] Trastuzumab Deruxtecan, (DS-8201), P-I study, HER2, Low Expressing
    Metastatic Breast Cancer

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post